The therapeutic landscape for severe obesity faces a critical tension: medications that drive substantial weight loss often compromise muscle mass and strength, potentially undermining long-term metabolic health. New evidence suggests this trade-off may be less problematic than previously assumed with newer GLP-1 receptor agonists.
The SEMALEAN study tracked 106 patients with severe obesity (average BMI 46.3) receiving semaglutide 2.4mg over 12 months, using DXA scanning and functional assessments to differentiate fat from lean tissue changes. Participants achieved meaningful weight reduction averaging 13% by one year, with fat mass declining 18% while lean mass dropped only initially (3kg at 7 months) before stabilizing. Crucially, handgrip strength—a validated predictor of overall muscle function and mortality risk—improved by 4.5kg despite the temporary lean mass reduction. The proportion meeting criteria for sarcopenic obesity fell from 49% to 33%.
This finding challenges conventional assumptions about GLP-1 medications inevitably causing problematic muscle loss. The strength gains alongside stabilized lean mass suggest the initial decline may reflect fluid shifts or metabolically inactive tissue rather than functional muscle fiber loss. However, the study's 12-month timeframe limits conclusions about longer-term muscle preservation, particularly given that metabolic adaptations often evolve beyond the first year. Women showed superior fat loss responses, while patients with diabetes or prior GLP-1 exposure demonstrated blunted effects—important considerations for personalized treatment approaches. These results support viewing muscle function, not just muscle mass, as the critical metric for assessing GLP-1 therapy outcomes.